Foghorn Therapeutics
FHTX | NASDAQ
$1.79
-$0.28 (-13.53%)
At close: Nov 16, 2026, 4:00 PM ET
$1.76
-$0.03 (-1.68%)
After-hours:
Nov 16, 2026, 4:34 PM ET
-13.53%
(1D)No price chart data available for 1D timeframe.
Rating
62.5
Fundamentals Strong
Market Sentiment Neutral
Moat None
Sector Rank #111/1021 (Top 11%)
Key Statistics
Market Data
Market Cap $127.91M
1D Range
1.77 2.05
52W Range
1.76 7.07
Valuation (TTM)
PE 29.83
PB -9.08
EV/EBITDA 1.43
Valuation (NTM)
Forward PE N/A
Forward PEG -0.32
Price Target $5.00
Cash Flow
FCF Yield -65.4%
SBC Adj. FCF Yield -73.0%
SBC Impact -11.6%
Margins
Gross Margin 99.1%
Operating Margin 5.9%
FCF Margin -74.6%
Growth (CAGR)
Revenue 3Y | 5Y 51.0% |
165.1%
Dil EPS 3Y | 5Y 99.0% |
41.6%
FCF 3Y | 5Y 11.0% |
-183.6%
Returns
ROA 4.9%
ROE -14.2%
ROIC 4.2%
Financial Health
Net Cash
$156.22M
Current Ratio 4.24
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within th...
Sector Healthcare
Industry Biotechnology
Employees 106
IPO Date Oct 23, 2020
Website foghorntx.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 9, 2026
EPS
$0.8
Beat +439.62%
YoY:
+420.00% REV
$83.54M
Beat +1077.13%
YoY:
+924.69%Next Earnings
Mar 10, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
6
Consensus
Hold
Price Target
$5.00
Upside
+179.33%
Buy (3)
Hold (3)
Sell (0)
Add to Watchlist
Select watchlists to add or remove FHTX